Edition:
United States

CymaBay Therapeutics Inc (CBAY.OQ)

CBAY.OQ on NASDAQ Stock Exchange Global Select Market

12.01USD
2:56pm EDT
Change (% chg)

$-0.79 (-6.17%)
Prev Close
$12.80
Open
$12.80
Day's High
$12.95
Day's Low
$11.96
Volume
94,225
Avg. Vol
249,045
52-wk High
$15.59
52-wk Low
$6.88

Chart for

About

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a... (more)

Overall

Beta: 1.90
Market Cap(Mil.): $755.88
Shares Outstanding(Mil.): 59.05
Dividend: --
Yield (%): --

Financials

  CBAY.OQ Industry Sector
P/E (TTM): -- 108.51 32.45
EPS (TTM): -0.93 -- --
ROI: -45.97 1.61 12.63
ROE: -47.49 0.35 14.80

BRIEF-CymaBay Therapeutics Q1 Loss Per Share $0.32

* CYMABAY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 08 2018

BRIEF-CymaBay Initiates Phase 2B Study Of Seladelpar In Patients With Non-Alcoholic Steatohepatitis

* CYMABAY THERAPEUTICS ANNOUNCES THE INITIATION OF A PHASE 2B STUDY OF SELADELPAR IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS

May 08 2018

BRIEF-Cymabay Announces 12-Week And 26-Week Results From Phase 2 Study Of Seladelpar In Patients With Primary Biliary Cholangitis

* WEEK RESULTS FROM ITS ONGOING PHASE 2 STUDY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AT THE INTERNATIONAL LIVER CONGRESS™ 2018

Apr 11 2018

Earnings vs. Estimates